Although some studies have suggested that RAS mutations are associated with reduced efficacy of trastuzumab in HER2-positive colorectal or gastric cancer,41 there is currently limited research on the role of RAS pathway mutations in anti-HER2 response among breast cancer patients. This evidence concerns the gene ERBB2 and breast carcinoma.